9.38 USD
-0.41 (-4.19%)
9.38 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 80% to DSGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 11.99. This target is 27.77% above the current price.
DSGN was analyzed by 9 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about DSGN.
In the previous month the buy percentage consensus was at a similar level.
DSGN was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-03 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-11-20 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-11-06 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-08-06 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-05-07 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-03-20 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-03-20 | Wedbush | Reiterate | Neutral -> Neutral |
| 2023-11-14 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2023-08-15 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2023-08-15 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2023-08-15 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-05-10 | RBC Capital | Maintains | Outperform |
| 2023-05-10 | Wedbush | Maintains | Outperform |
| 2023-05-04 | Goldman Sachs | Upgrade | Sell -> Neutral |
| 2023-03-15 | RBC Capital | Reiterate | Outperform |
| 2022-12-09 | SVB Leerink | Maintains | Outperform |
| 2022-12-08 | RBC Capital | Maintains | Outperform |
| 2022-08-09 | Wedbush | Maintains | Outperform |
| 2022-06-10 | Wedbush | Initiate | Outperform |
| 2022-05-24 | Goldman Sachs | Maintains | Sell |
| 2022-05-10 | SVB Leerink | Maintains | Outperform |
| 2022-05-02 | RBC Capital | Initiate | Outperform |
| 2022-01-19 | Goldman Sachs | Initiate | Sell |
| 2021-04-20 | SVB Leerink | Initiate | Outperform |
| 2021-04-20 | Goldman Sachs | Initiate | Neutral |
| 2021-04-20 | Piper Sandler | Initiate | Overweight |
DESIGN THERAPEUTICS INC / DSGN FAQ
What is the price target for DSGN stock?
9 analysts have analysed DSGN and the average price target is 11.99 USD. This implies a price increase of 27.77% is expected in the next year compared to the current price of 9.38.
Can you provide the consensus rating for DESIGN THERAPEUTICS INC stock?
The consensus rating for DESIGN THERAPEUTICS INC (DSGN) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.